Logo

Life Technologies to Report Financials Around Realigned Business Groups

Apr 12, 2012

NEW YORK (GenomeWeb News) – Life Technologies will be reporting its financial results in three new business groups to better reflect its internal organization and end markets, the company said in a regulatory filing after the close of the market on Wednesday.

Starting with the first quarter ended March 31, Life Tech's financial results will be reported for Research Consumables, Genetic Analysis, and Applied Sciences. Results had been grouped around the firm's technology platforms Molecular Biology Systems, Genetic Systems, and Cell Systems.

The changes have no impact on consolidated results of operations, financial conditions, or cash flow, Life Tech said in the document filed with the US Securities and Exchange Commission.

Life Tech's first-quarter earnings results are scheduled to be announced after the close of the market on April 24.

Filed under

financial results
Thermo Fisher Scientific
Breaking News
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.